UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:August 19,
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Marker Therapeutics Charts.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Marker Therapeutics Charts.

Marker Therapeutics, Inc. News

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 
Monday 8 April 2024 (4 weeks ago) • GlobeNewswire Inc.
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Friday 22 March 2024 (1 month ago) • GlobeNewswire Inc.
Form 8-K - Current report
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Monday 26 February 2024 (2 months ago) • Edgar (US Regulatory)
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Monday 22 January 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Monday 8 January 2024 (4 months ago) • Edgar (US Regulatory)
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Monday 8 January 2024 (4 months ago) • GlobeNewswire Inc.
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
Thursday 21 December 2023 (4 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Monday 11 December 2023 (5 months ago) • Edgar (US Regulatory)
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
Monday 11 December 2023 (5 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Monday 20 November 2023 (5 months ago) • Edgar (US Regulatory)

More Marker Therapeutics, Inc. News Articles